Narciclasine In Vitro Characterization: Solubility, Metabolic Stability, and P-gp Status

A supplementary document from figshare details the in vitro pharmacological characterization of the anticancer compound narciclasine. The study, authored by Ravi Akkireddy and last updated in April 2026, developed an HPLC-tandem mass spectrometry assay to measure solubility, metabolic stability in human liver microsomes, and P-glycoprotein substrate status using Caco-2 and cytotoxicity assays.

Use Cases

• Benchmarking metabolic stability of new anticancer compounds based on the reported human liver microsome and hepatocyte data
• Informing drug design for improved solubility based on the measured lipophilicity and pH-dependent solubility profiles
• Assessing P-glycoprotein interaction risk for drug candidates based on the comparative cytotoxicity assay methodology described

Strengths

• Provides specific quantitative results, including a lipophilicity value of 0.40 and stability data across four species
• Methodology is detailed, covering multiple assay types (HPLC-MS, Caco-2 permeability, cytotoxicity)
• Released under a permissive CC-BY-4.0 license for reuse

Limitations

• The dataset is a 244.7 KB DOCX file, suggesting limited scope and primarily textual, non-tabular results
• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment for quantitative analysis

Provenance

Source

figshare

Collection Method

In vitro laboratory assays including HPLC-tandem mass spectrometry, Caco-2 permeability, and cytotoxicity tests.

Time Range

Study period not specified; document last updated April 2026.

Freshness

Last updated 2026-04 28 05:24:19; freshness should be verified

Geography

Geographic scope of the research is not specified.